New polymer systems will be featured players in a bevy of new drug-eluting stents set to enter the market. The stents are placed in blood vessels close to the heart with the intent of releasing drugs that keep arteries open with patients who suffer from arteriosclerosis. It’s become a multi-billion dollar business with a couple of star players, and a spectacular technology display for high tech plastics. One of the exciting new entries features a bioresorbale polymer, first predicted by Design News. This is a plastic that disintegrates within six months, leaving just the cobalt chromium metal stent to prop open the artery. It comes in the Costar system from Conor Medical Systems. Conor was recently acquired by J&J. Abbott is developing a stent that is made of bioresobrale resin, specifically polylactic acid (PLA). It isn’t expected to hit the market for another five years. The new technologies in the stent business were reviewed yesterday at a cardiology meeting called CRT 2007 (Cardiovascular Revascularization Therapies) in Washington DC. My take: It will take a longer for new exciting technologies to make it to the operating table because of lingering questions about the effects of the original drug-eluting polymer stents. The questions focus more on the drugs than the polymers, but this one of the most exciting technology development areas for plastics on the planet.
Focus on Fundamentals consists of 45-minute on-line classes that cover a host of technologies. You learn without leaving the comfort of your desk. All classes are taught by subject-matter experts and all are archived. So if you can't attend live, attend at your convenience.